+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Surgical Site Infections (SSI) - Pipeline Insight, 2020

  • ID: 4989278
  • Clinical Trials
  • February 2020
  • Region: Global
  • 106 Pages
  • DelveInsight

FEATURED COMPANIES

  • Menarini Group
  • PolyPid Ltd.
Surgical Site Infections (SSI) Overview

Surgical Site Infections (SSI) Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Surgical Site Infections (SSI) market. A detailed picture of the Surgical Site Infections (SSI) pipeline landscape is provided, which includes the disease overview and Surgical Site Infections (SSI) treatment guidelines. The assessment part of the report embraces in-depth Surgical Site Infections (SSI) commercial assessment and clinical assessment of the Surgical Site Infections (SSI) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Surgical Site Infections (SSI) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Surgical Site Infections (SSI) of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Surgical Site Infections (SSI) with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Surgical Site Infections (SSI) treatment.
  • Surgical Site Infections (SSI) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Surgical Site Infections (SSI) market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Surgical Site Infections (SSI) Analytical Perspective

In-depth Surgical Site Infections (SSI) Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Surgical Site Infections (SSI) Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Surgical Site Infections (SSI) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Surgical Site Infections (SSI) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Surgical Site Infections (SSI) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Surgical Site Infections (SSI) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Surgical Site Infections (SSI) .

Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Surgical Site Infections (SSI) .
  • In the coming years, the Surgical Site Infections (SSI) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Surgical Site Infections (SSI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Surgical Site Infections (SSI) treatment market. Several potential therapies for Surgical Site Infections (SSI) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Surgical Site Infections (SSI) market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Surgical Site Infections (SSI) ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions
  • What are the current options for Surgical Site Infections (SSI) treatment?
  • How many companies are developing therapies for the treatment of Surgical Site Infections (SSI)?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Surgical Site Infections (SSI)?
  • How many Surgical Site Infections (SSI) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Surgical Site Infections (SSI)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Surgical Site Infections (SSI) market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Surgical Site Infections (SSI)?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Surgical Site Infections (SSI) therapies?
  • What are the clinical studies going on for Surgical Site Infections (SSI) and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Surgical Site Infections (SSI)?
  • How many patents are granted and pending for the emerging therapies for the treatment of Surgical Site Infections (SSI)?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Menarini Group
  • PolyPid Ltd.

1. Report Introduction
2. Surgical Site Infections (SSI)
2.1. Overview
2.2. History
2.3. Surgical Site Infections (SSI) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Surgical Site Infections (SSI) Diagnosis
2.6.1. Diagnostic Guidelines
3. Surgical Site Infections (SSI) Current Treatment Patterns
3.1. Surgical Site Infections (SSI) Treatment Guidelines
4. Surgical Site Infections (SSI) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Surgical Site Infections (SSI) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Surgical Site Infections (SSI) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Surgical Site Infections (SSI) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Surgical Site Infections (SSI) Late Stage Products (Phase-III)7. Surgical Site Infections (SSI) Mid Stage Products (Phase-II)8. Early Stage Products (Phase-I)9. Pre-clinical Products and Discovery Stage Products10. Inactive Products11. Dormant Products12. Surgical Site Infections (SSI) Discontinued Products
13. Surgical Site Infections (SSI) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Surgical Site Infections (SSI) Key Companies15. Surgical Site Infections (SSI) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Surgical Site Infections (SSI) Unmet Needs18. Surgical Site Infections (SSI) Future Perspectives19. Surgical Site Infections (SSI) Analyst Review20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Menarini Group
  • Professional Disposables International, Inc.
  • PolyPid Ltd.
Note: Product cover images may vary from those shown